FINWIRES · TerminalLIVE
FINWIRES

SGX:42C

11 stories mentioning SGX:42CUpdated 13d ago

Every FINWIRES story that references SGX:42C, newest first.

What's the latest news on SGX:42C?

Asia

US Declaration Clears Path for iX Biopharma Pain Drug; Shares Jump 13%

iX Biopharma (SGX:42C) said a recent US regulatory development has cleared the way for it to advance its Wafermine Emergency Use Authorization (EUA) submission to the US Food and Drug Administration (US FDA), according to a Monday filing to the Singapore stock exchange.The company's shares jumped nearly 13% in recent trade.In a recent declaration, the US government opened an emergency use pathway for drugs to treat moderate-to-severe acute pain in military casualties. The move will allow the US FDA to consider an EUA for the Wafermine drug.iX Biopharma said it expects to complete its EUA submission to the US regulator in the fourth quarter of 2026.If granted, an EUA would allow Wafermine to be deployed for authorized use by US military personnel before full US FDA approval.

SGX:42C
Asia

Singapore Shares Track Regional Losses Amid US-Iran Standoff; OUE Healthcare Surges 23%

Singapore shares plunged on Monday, tracking regional losses as the US-Iran conflict took a new turn with the US Treasury Secretary Scott Bessent expected to provide details of Washington's "economic D-Day" play for Iran.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 5,673.71 and 5,715.47 throughout the day. It ended the session at 5,680.46, down 8.50 points or 0.2% compared to Friday's close.In economic news, Singapore's core consumer price index (CPI), which excludes accommodation and private transport costs, rose 2% year over year in July, according to joint data released by the Monetary Authority of Singapore (MAS) and the Ministry of Trade and Industry (MTI).On the corporate front, shares of OUE Healthcare (SGX:5WA) surged over 23% at the close as it received a proposal to be taken private via a scheme of arrangement, with scheme shareholders to receive SG$0.050 per share.iX Biopharma's (SGX:42C) shares dipped nearly 9% at the close as its net loss attributable to equity holders widened 196% to SG$5.0 million during the fiscal fourth quarter ended June 30 from SG$1.7 million a year earlier.Meanwhile, Pacific Century Regional Developments (SGX:P15) subsidiary, PCRD Services, agreed to sell its indirect 49.87% stake in India's KSH Distriparks to Delhi International Cargo Terminal for around SG$19.3 million.

^STISGX:42CSGX:5WASGX:P15
Asia

iX Biopharma's Net Loss Nearly Triples in Fiscal Q4; Shares Slump 9%

iX Biopharma's (SGX:42C) net loss attributable to equity holders widened 196% to SG$5.0 million during the fiscal fourth quarter ended June 30 from SG$1.7 million a year earlier.Loss per share came in at SG$0.0048 compared with SG$0.0019 in the year-ago period, according to a Friday filing with the Singapore Exchange.Revenue fell 7% year over year to SG$2.1 million from SG$2.2 million.Shares of the healthcare provider were down nearly 9% Monday morning.

SGX:42C
Asia

iX Biopharma Reports 92% Warrants Exercise

iX Biopharma (SGX:42C) said warrant holders have exercised about 92% of the warrants issued under its 2024 rights issue by July 15, converting them into roughly 53 million new shares, according to a Thursday Singapore Exchange filing.Management and directors accounted for around 24.2 million shares, or 46% of all warrants exercised, reflecting strong insider confidence.The warrant exercises raised most of the potential SG$3.5 million in proceeds, which iX Biopharma said will support its balance sheet and U.S. expansion through the compounding pharmacy pathway.

SGX:42C
Asia

Singapore Shares Remain Upbeat on US-Iran Peace Deal; Global Invacom Crashes 17%

Singapore shares remained upbeat on Tuesday, tracking broader regional gains as investors' sentiment was uplifted by the US and Iran's deal to reopen the Strait of Hormuz.The Straits Times Index (STI), a key benchmark for the Singapore Exchange, ranged between 5,075.34 and 5,122.09 throughout the day. It ended the session at 5,116.86, up 39.57 points or 0.8% compared to Monday's close.On the corporate front, shares of Global Invacom (SGX:QS9) plunged nearly 17% with the company targeting to raise up to SG$4.9 million for satellite technology expansion via a renounceable partially-underwritten rights issue of up to 140 million shares at SG$0.035 per share.IX Biopharma (SGX:42C) closed over 8% lower as it unveiled plans to relocate its manufacturing equipment from its facility in Australia to a 503B-licensed plant in Nevada, U.S.Meanwhile, shares of Jardine Matheson (SGX:J36) closed nearly 4% lower as it unveiled a new $500 million share buyback program, slated for conclusion by the end of 2027.

^STISGX:42CSGX:J36SGX:QS9
Asia

IX Biopharma to Relocate Manufacturing Equipment to US; Shares Fall 8%

IX Biopharma (SGX:42C) will relocate its manufacturing equipment from its facility in Australia to a 503B-licensed plant in Nevada, U.S., according to a Monday filing with the Singapore Exchange.Shares of the healthcare services company were down over 8% in Tuesday's late-morning trading.The plant is managed by the company's joint venture partner, Orion Specialty Labs, and the relocation is expected to be completed in the third quarter of the year.The move also comes after the company secured a $41 million US Department of Defense contract.The relocation comes in the wake of the US unveiling tariffs of up to 100% on pharmaceutical imports from Australia.

SGX:42C
Asia

iX Biopharma Secures Listing and Quotation Notice for New Shares; Shares Zoom 11%

iX Biopharma (SGX:42C) received a listing and quotation notice from the Singapore Exchange Securities Trading for 1.3 million shares, according to a Thursday filing with the Singapore Exchange.Shares of the pharmaceutical and nutraceutical company surged nearly 11% in Monday trading.The notice is subject to shareholder approval and compliance with the bourse's listing requirements, the filing added.

SGX:42C
Asia

iX Biopharma Allots, Issues Nearly 1.2 Million Shares

iX Biopharma (SGX:42C) allotted and issued nearly 1.2 million shares at SG$0.06 per share, pursuant to the exercise of warrants, according to a Thursday filing with the Singapore Exchange.Following the issue, the company's share capital increased to close to 1.05 billion shares, with the new shares expected to be listed and quoted on or around April 27.

SGX:42C
Asia

iX Biopharma Allots, Issues Over 1.2 Million Shares

iX Biopharma (SGX:42C) allotted and issued 1.2 million shares at SG$0.06 per share, pursuant to the exercise of warrants, according to a Wednesday filing with the Singapore Exchange.Following the issue, the company's share capital increased to 1.05 billion shares, with the new shares expected to be listed and quoted on April 21.

SGX:42C
Asia

iX Biopharma to Issue Over 1 Million Shares to Anson Properties; Shares Down 3%

IX Biopharma (SGX:42C) signed a subscription agreement with Anson Properties to raise SG$440,537 through the issuance of 1,045,164 new shares at SG$0.4215 per share, according to a Thursday filing with the Singapore Exchange.Shares of the pharmaceutical company were down over 3% in Friday trading.Proceeds raised from the subscription will be used for general working capital needs.The company also proposed to issue 304,270 shares at SG$0.4215 per share to certain directors, in connection with the directors' fees for the period from Oct. 1 2025, till March 31, 2026.

SGX:42C
Asia

Taka Jewelry Names Group Financial Controller

Taka Jewelry (SGX:42L) named Cheah Lai Min as its group financial controller, effective May 4, according to a Monday filing with the Singapore Exchange.Min previously served as a finance manager at iX Biopharma (SGX:42C), the filing showed.

SGX:42CSGX:42L

Track with the FINWIRES app suite

FolioX
FolioX
Track SGX:42C in your portfolio
WheelAI
WheelAI
Analyze SGX:42C options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SGX:42C